Single tube liquid biopsy for advanced non-small cell lung cancer

Sanne de Wit, Elisabetta Rossi, Sabrina Weber, Menno Tamminga, Mariangela Manicone, Joost F. Swennenhuis, Catharina G.M. Groothuis-Oudshoorn, Riccardo Vidotto, Antonella Facchinetti, Leonie L. Zeune, Ed Schuuring, Rita Zamarchi, T. Jeroen N. Hiltermann, Michael R. Speicher, Ellen Heitzer, Leon W.M.M. Terstappen, Harry J.M. Groen* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)
3 Downloads (Pure)

Abstract

The need for a liquid biopsy in non-small cell lung cancer (NSCLC) patients is rapidly increasing. We studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a single blood draw in advanced NSCLC patients: EpCAMhigh circulating tumor cells (CTC), EpCAMlow CTC, tumor-derived extracellular vesicles (tdEV) and cell-free circulating tumor DNA (ctDNA). EpCAMhigh CTC were detected with CellSearch, tdEV in the CellSearch images and EpCAMlow CTC with filtration after CellSearch. ctDNA was isolated from plasma and mutations present in the primary tumor were tracked with deep sequencing methods. In 97 patients, 21% had ≥2 EpCAMhigh CTC, 15% had ≥2 EpCAMlow CTC, 27% had ≥18 tdEV and 19% had ctDNA with ≥10% mutant allele frequency. Either one of these four biomarkers could be detected in 45% of the patients and all biomarkers were present in 2%. In 11 out of 16 patients (69%) mutations were detected in the ctDNA. Two or more unfavorable biomarkers were associated with poor OS. The presence of EpCAMhigh CTC and elevated levels of tdEV and ctDNA was associated with a poor OS; however, the presence of EpCAMlow CTC was not. This single tube approach enables simultaneous analysis of multiple biomarkers to explore their potential as a liquid biopsy.

Original languageEnglish
Pages (from-to)3127-3137
Number of pages11
JournalInternational journal of cancer
Volume144
Issue number12
Early online date11 Dec 2018
DOIs
Publication statusPublished - 15 Jun 2019

Fingerprint

Circulating Neoplastic Cells
Non-Small Cell Lung Carcinoma
Biopsy
Neoplasms
Biomarkers
DNA
Survival
High-Throughput Nucleotide Sequencing
Mutation
Tumor Biomarkers
Gene Frequency

Keywords

  • UT-Hybrid-D
  • circulating tumor cells
  • circulating tumor DNA
  • EpCAM
  • extracellular vesicles
  • liquid biopsy
  • non-small cell lung cancer
  • survival
  • biomarkers

Cite this

de Wit, S., Rossi, E., Weber, S., Tamminga, M., Manicone, M., Swennenhuis, J. F., ... Groen, H. J. M. (2019). Single tube liquid biopsy for advanced non-small cell lung cancer. International journal of cancer, 144(12), 3127-3137. https://doi.org/10.1002/ijc.32056
de Wit, Sanne ; Rossi, Elisabetta ; Weber, Sabrina ; Tamminga, Menno ; Manicone, Mariangela ; Swennenhuis, Joost F. ; Groothuis-Oudshoorn, Catharina G.M. ; Vidotto, Riccardo ; Facchinetti, Antonella ; Zeune, Leonie L. ; Schuuring, Ed ; Zamarchi, Rita ; Hiltermann, T. Jeroen N. ; Speicher, Michael R. ; Heitzer, Ellen ; Terstappen, Leon W.M.M. ; Groen, Harry J.M. / Single tube liquid biopsy for advanced non-small cell lung cancer. In: International journal of cancer. 2019 ; Vol. 144, No. 12. pp. 3127-3137.
@article{985aeb3c9f23476a9febb2e7923d82b2,
title = "Single tube liquid biopsy for advanced non-small cell lung cancer",
abstract = "The need for a liquid biopsy in non-small cell lung cancer (NSCLC) patients is rapidly increasing. We studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a single blood draw in advanced NSCLC patients: EpCAMhigh circulating tumor cells (CTC), EpCAMlow CTC, tumor-derived extracellular vesicles (tdEV) and cell-free circulating tumor DNA (ctDNA). EpCAMhigh CTC were detected with CellSearch, tdEV in the CellSearch images and EpCAMlow CTC with filtration after CellSearch. ctDNA was isolated from plasma and mutations present in the primary tumor were tracked with deep sequencing methods. In 97 patients, 21{\%} had ≥2 EpCAMhigh CTC, 15{\%} had ≥2 EpCAMlow CTC, 27{\%} had ≥18 tdEV and 19{\%} had ctDNA with ≥10{\%} mutant allele frequency. Either one of these four biomarkers could be detected in 45{\%} of the patients and all biomarkers were present in 2{\%}. In 11 out of 16 patients (69{\%}) mutations were detected in the ctDNA. Two or more unfavorable biomarkers were associated with poor OS. The presence of EpCAMhigh CTC and elevated levels of tdEV and ctDNA was associated with a poor OS; however, the presence of EpCAMlow CTC was not. This single tube approach enables simultaneous analysis of multiple biomarkers to explore their potential as a liquid biopsy.",
keywords = "UT-Hybrid-D, circulating tumor cells, circulating tumor DNA, EpCAM, extracellular vesicles, liquid biopsy, non-small cell lung cancer, survival, biomarkers",
author = "{de Wit}, Sanne and Elisabetta Rossi and Sabrina Weber and Menno Tamminga and Mariangela Manicone and Swennenhuis, {Joost F.} and Groothuis-Oudshoorn, {Catharina G.M.} and Riccardo Vidotto and Antonella Facchinetti and Zeune, {Leonie L.} and Ed Schuuring and Rita Zamarchi and Hiltermann, {T. Jeroen N.} and Speicher, {Michael R.} and Ellen Heitzer and Terstappen, {Leon W.M.M.} and Groen, {Harry J.M.}",
note = "Wiley deal",
year = "2019",
month = "6",
day = "15",
doi = "10.1002/ijc.32056",
language = "English",
volume = "144",
pages = "3127--3137",
journal = "International journal of cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

de Wit, S, Rossi, E, Weber, S, Tamminga, M, Manicone, M, Swennenhuis, JF, Groothuis-Oudshoorn, CGM, Vidotto, R, Facchinetti, A, Zeune, LL, Schuuring, E, Zamarchi, R, Hiltermann, TJN, Speicher, MR, Heitzer, E, Terstappen, LWMM & Groen, HJM 2019, 'Single tube liquid biopsy for advanced non-small cell lung cancer', International journal of cancer, vol. 144, no. 12, pp. 3127-3137. https://doi.org/10.1002/ijc.32056

Single tube liquid biopsy for advanced non-small cell lung cancer. / de Wit, Sanne; Rossi, Elisabetta; Weber, Sabrina; Tamminga, Menno; Manicone, Mariangela; Swennenhuis, Joost F.; Groothuis-Oudshoorn, Catharina G.M.; Vidotto, Riccardo; Facchinetti, Antonella; Zeune, Leonie L.; Schuuring, Ed; Zamarchi, Rita; Hiltermann, T. Jeroen N.; Speicher, Michael R.; Heitzer, Ellen; Terstappen, Leon W.M.M.; Groen, Harry J.M. (Corresponding Author).

In: International journal of cancer, Vol. 144, No. 12, 15.06.2019, p. 3127-3137.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Single tube liquid biopsy for advanced non-small cell lung cancer

AU - de Wit, Sanne

AU - Rossi, Elisabetta

AU - Weber, Sabrina

AU - Tamminga, Menno

AU - Manicone, Mariangela

AU - Swennenhuis, Joost F.

AU - Groothuis-Oudshoorn, Catharina G.M.

AU - Vidotto, Riccardo

AU - Facchinetti, Antonella

AU - Zeune, Leonie L.

AU - Schuuring, Ed

AU - Zamarchi, Rita

AU - Hiltermann, T. Jeroen N.

AU - Speicher, Michael R.

AU - Heitzer, Ellen

AU - Terstappen, Leon W.M.M.

AU - Groen, Harry J.M.

N1 - Wiley deal

PY - 2019/6/15

Y1 - 2019/6/15

N2 - The need for a liquid biopsy in non-small cell lung cancer (NSCLC) patients is rapidly increasing. We studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a single blood draw in advanced NSCLC patients: EpCAMhigh circulating tumor cells (CTC), EpCAMlow CTC, tumor-derived extracellular vesicles (tdEV) and cell-free circulating tumor DNA (ctDNA). EpCAMhigh CTC were detected with CellSearch, tdEV in the CellSearch images and EpCAMlow CTC with filtration after CellSearch. ctDNA was isolated from plasma and mutations present in the primary tumor were tracked with deep sequencing methods. In 97 patients, 21% had ≥2 EpCAMhigh CTC, 15% had ≥2 EpCAMlow CTC, 27% had ≥18 tdEV and 19% had ctDNA with ≥10% mutant allele frequency. Either one of these four biomarkers could be detected in 45% of the patients and all biomarkers were present in 2%. In 11 out of 16 patients (69%) mutations were detected in the ctDNA. Two or more unfavorable biomarkers were associated with poor OS. The presence of EpCAMhigh CTC and elevated levels of tdEV and ctDNA was associated with a poor OS; however, the presence of EpCAMlow CTC was not. This single tube approach enables simultaneous analysis of multiple biomarkers to explore their potential as a liquid biopsy.

AB - The need for a liquid biopsy in non-small cell lung cancer (NSCLC) patients is rapidly increasing. We studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a single blood draw in advanced NSCLC patients: EpCAMhigh circulating tumor cells (CTC), EpCAMlow CTC, tumor-derived extracellular vesicles (tdEV) and cell-free circulating tumor DNA (ctDNA). EpCAMhigh CTC were detected with CellSearch, tdEV in the CellSearch images and EpCAMlow CTC with filtration after CellSearch. ctDNA was isolated from plasma and mutations present in the primary tumor were tracked with deep sequencing methods. In 97 patients, 21% had ≥2 EpCAMhigh CTC, 15% had ≥2 EpCAMlow CTC, 27% had ≥18 tdEV and 19% had ctDNA with ≥10% mutant allele frequency. Either one of these four biomarkers could be detected in 45% of the patients and all biomarkers were present in 2%. In 11 out of 16 patients (69%) mutations were detected in the ctDNA. Two or more unfavorable biomarkers were associated with poor OS. The presence of EpCAMhigh CTC and elevated levels of tdEV and ctDNA was associated with a poor OS; however, the presence of EpCAMlow CTC was not. This single tube approach enables simultaneous analysis of multiple biomarkers to explore their potential as a liquid biopsy.

KW - UT-Hybrid-D

KW - circulating tumor cells

KW - circulating tumor DNA

KW - EpCAM

KW - extracellular vesicles

KW - liquid biopsy

KW - non-small cell lung cancer

KW - survival

KW - biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85060912389&partnerID=8YFLogxK

U2 - 10.1002/ijc.32056

DO - 10.1002/ijc.32056

M3 - Article

AN - SCOPUS:85060912389

VL - 144

SP - 3127

EP - 3137

JO - International journal of cancer

JF - International journal of cancer

SN - 0020-7136

IS - 12

ER -

de Wit S, Rossi E, Weber S, Tamminga M, Manicone M, Swennenhuis JF et al. Single tube liquid biopsy for advanced non-small cell lung cancer. International journal of cancer. 2019 Jun 15;144(12):3127-3137. https://doi.org/10.1002/ijc.32056